Noile-Immune Biotech Inc. (JP:4893)

:4893

4893

Noile-Immune Biotech Inc.

RESEARCH TOOLSreports

Want to see JP:4893 full AI Analyst Report?

Noile-Immune Biotech Inc. (4893) Price & Analysis

0 Followers

4893 Stock Chart & Stats

¥134.00

¥9.00(4.81%)

At close: Jan 08 4:00 PM EST

¥134.00

¥9.00(4.81%)

Day’s Range― - ―

52-Week Range¥117.00 - ¥217.00

Previous CloseN/A

Volume1.93M

Average Volume (3M)85.17K

Market Cap

¥5.11B

Enterprise Value¥2.10B

Total Cash (Recent Filing)¥4.31B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.46

Next Earnings

Aug 07, 2026

EPS Estimate

-5.51

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-15.99

Shares Outstanding43,276,764

10 Day Avg. Volume110,290

30 Day Avg. Volume85,173

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.46

Price to Sales (P/S)1151.82

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-34

Revenue Forecast (FY)¥300.00M

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet (no Debt)No reported debt materially reduces solvency and refinancing risk, giving the company strategic flexibility to fund R&D, pursue partnerships, or bridge financing. That balance-sheet strength lengthens runway and supports long-term development plans despite operating losses.

Very High Gross MarginsNear-100% gross margins imply highly scalable unit economics from proprietary therapies or services. If revenue recovery occurs, this margin profile delivers strong operating leverage and pricing power, enabling a quicker pathway to sustainable profitability once fixed costs and R&D are controlled.

Positioned In Cell-based ImmunotherapiesFocus on engineered immune-cell therapies targets a structurally expanding oncology market with high unmet need and active partnering/commercialization opportunities. This strategic industry exposure supports durable growth prospects and potential partner interest even before self-commercialization.

Bears Say

Sharp Revenue ContractionSustained, large revenue declines undermine operating leverage and signal weakening product, licensing, or service traction. Continued top-line shrinkage pressures margins, reduces internal funding ability for trials, and lengthens the timeline to reach commercial sustainability or attractive partnering outcomes.

Persistent Negative Operating Cash FlowOperating cash flow has been negative across reported years and free cash flow remains largely negative, indicating ongoing cash burn. Even with some improvement in 2025, the company depends on external funding, increasing dilution and execution risk if capital markets or partners retreat.

Negative Returns On EquityPersistently negative ROE shows shareholder capital isn't generating returns and ongoing losses erode equity. Over time this reduces the firm's financial buffer, makes future raises costlier, and constrains strategic options for funding clinical programs or scaling operations.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥117.00 and its highest was ¥217.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥5.11B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 56 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on May 14, 2026. The company reported -¥3.54 earnings per share for the quarter, beating the consensus estimate of -¥5.05 by ¥1.51.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate is -5.51.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,276,764 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥3.54 in its last earnings report, beating expectations of -¥5.05. Following the earnings report the stock price went down -3.356%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Established in 2015 and based in Minato, Japan, this company is dedicated to exploring and advancing CAR-T cell technology for use in cancer immunotherapy treatments.